Our global life sciences company brings diagnostic testing & drug development together.

β2-Glycoprotein 1 Antibodies, IgA, IgG, IgM

CPT: 86146(x3)
Print Share


  • Anti-β2 Glycoprotein 1
  • Beta-2 Glycoprotein 1 Antibodies, IgG, IgA, IgM

Test Includes

Semiquantitative results for IgG, IgM, and IgA antibodies against β2-glycoproteins

Expected Turnaround Time

2 - 3 days

Related Documents

For more information, please view the literature below.

Procedures for Hemostasis and Thrombosis: A Clinical Test Compendium

Specimen Requirements




1 mL

Minimum Volume

0.5 mL


Red-top tube or gel-barrier tube

Storage Instructions


Stability Requirements



Room temperature

7 days


7 days


7 days

Freeze/thaw cycles

Stable x3

Test Details


Assess the risk of thrombosis in patients who may be at risk for antiphospholipid syndrome (APS). This test should be used in conjunction with current traditional anticardiolipin and anticoagulant tests.1


Anti-β2-glycoprotein 1 should not be used alone as a screening test for antiphospholipid syndrome.


Enzyme-linked immunosorbent assay (ELISA) to detect antibodies binding to a microtiter plate coated with purified β2-glycoprotein 1 antigen

Reference Interval

• IgA = 0−25 GP1 IgA units

• IgM = 0−32 GP1 IgM units

• IgG = 0−20 GP1 IgG units

Additional Information

Recently, an international consensus group of experts in the diagnosis and management of antiphospholipid syndrome (APS) concluded that β2-GP1 IgG and IgM antibodies should be included as diagnostic criteria for APS.2 This group determined that the presence of one or both of these antibodies is an independent risk factor for thrombosis and pregnancy complications.3

A common aspect to all assays for anticardiolipin antibodies (ACA) is the requirement that the assay system include a source of plasma proteins.3 It has been determined that, in many patients, β2-glycoprotein 1 (β2-GP1) is the plasma factor required for ACA binding.3,4 Solid-phase enzyme immunoassays that detect antibodies that bind to β2-GP1 in the absence of phospholipid are now part of the diagnostic arsenal for APS. β2-GP1-dependent binding is frequently detected in patients with clinical symptoms of APS.3 All three isotypes of anti-β2-GP1 (IgG, IgM, and IgA) have been associated with thrombosis.3,5,6 ACA that do not require β2-GP1 are usually transient and not clinically significant. Studies have shown that ACA associated with infections tend to not be β2-GP1-dependent.4 This supports the conclusion that anti-β2-GP1 assays may be more specific for APS than ACA.4,7,8 While the majority of patients with LA will also test positive for ACA and β2-GP1 antibodies, approximately 30% of patients tested will have discordant results.9,10 Approximately 20% of patients who test negative for ACA will test positive for β2-GP1.9 Anti-β2-GP1 testing can be useful in the evaluation of patients with positive ACA results and a clinical picture that is not consistent with APS.3,4,8 A negative anti-β2-GP1 result in this context would not support a diagnosis of APS. Anti-β2-GP1 testing can also support the diagnosis of APS in patients with a strong clinical picture for APS with negative LA and ACA results.8


6. Adcock DM, Bethel MA, Macy PA. Coagulation Handbook. Aurora, Colo: Esoterix−Colorado Coagulation; 2006.
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb; 4(2):295-306. 16420554
3. Reddel SW, Krilis SA. Testing for and clinical significance of anticardiolipin antibodies. Clin Diagn Lab Immunol. 1999 Nov; 6(6):775-782. 10548562
4. Carreras LO, Forastiero RR, Martinuzzo ME. Which are the best biological markers of the antiphospholipid syndrome? J Autoimmun. 2000 Sep; 15(2):163-172. 10968904
5. Brey RL, Abbott RD, Curb JD, et al. beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: The Honolulu Heart Program. Stroke. 2001 Aug; 32(8):1701-1706. 11486093
6. Greco TP, Amos MD, Conti-Kelly AM, Naranjo JD, Ijdo JW. Testing for the antiphospholipid syndrome: Importance of IgA anti-beta 2-glycoprotein I. Lupus. 2000; 9(1):33-41. 10713645
7. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002 Mar 7; 346(10):752-763. 11882732
8. Harris EN, Pierangeli SS, Gharavi AE. Diagnosis of the antiphospholipid syndrome: A proposal for use of laboratory tests. Lupus. 1998; 7(Suppl 2):S144-S148. 9814693
9. Hirsh J, Anand SS, Halperin JL, Fuster V; American Heart Association. Guide to anticoagulant therapy: Heparin: A statement for healthcare professionals from the American Heart Association. Circulation. 2001 Jun 19; 103(24):2994-3018. 11413093
10. Triplett DA. Coagulation abnormalities. In: McClatchey KD, ed. Clinical Laboratory Medicine. 2nd ed. Philadelphia, Pa: Lippincott Williams and Wilkins; 2002:1033-1049.


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
163915 Beta-2 Glycoprotein I Ab,G,A,M 56152-2 163881 Beta-2 Glycoprotein I Ab, IgG GPI IgG units 16135-6
163915 Beta-2 Glycoprotein I Ab,G,A,M 56152-2 163899 Beta-2 Glycoprotein I Ab, IgA GPI IgA units 21108-6
163915 Beta-2 Glycoprotein I Ab,G,A,M 56152-2 163907 Beta-2 Glycoprotein I Ab, IgM GPI IgM units 16136-4

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at